These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

157 related articles for article (PubMed ID: 35163016)

  • 21. New insights into the pathogenesis of chronic lymphocytic leukemia.
    Klein U; Dalla-Favera R
    Semin Cancer Biol; 2010 Dec; 20(6):377-83. PubMed ID: 21029776
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Molecular allelokaryotyping of early-stage, untreated chronic lymphocytic leukemia.
    Lehmann S; Ogawa S; Raynaud SD; Sanada M; Nannya Y; Ticchioni M; Bastard C; Kawamata N; Koeffler HP
    Cancer; 2008 Mar; 112(6):1296-305. PubMed ID: 18246537
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Acquired genomic copy number aberrations and survival in chronic lymphocytic leukemia.
    Ouillette P; Collins R; Shakhan S; Li J; Peres E; Kujawski L; Talpaz M; Kaminski M; Li C; Shedden K; Malek SN
    Blood; 2011 Sep; 118(11):3051-61. PubMed ID: 21795749
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multicolor FISH in chronic lymphocytic leukemia. An interphase study of patients with early-onset disease.
    Doneda L; Castorina P; Tedeschi A; Intropido L; Morra E; Montillo M; Larizza L
    Cancer Genet Cytogenet; 2001 Feb; 125(1):63-9. PubMed ID: 11297770
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.
    Stilgenbauer S; Bullinger L; Lichter P; Döhner H;
    Leukemia; 2002 Jun; 16(6):993-1007. PubMed ID: 12040431
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genomic abnormalities in chronic lymphocytic leukemia influence gene expression by a gene dosage effect.
    Dickinson JD; Joshi A; Iqbal J; Sanger W; Bierman PJ; Joshi SS
    Int J Mol Med; 2006 May; 17(5):769-78. PubMed ID: 16596259
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Validation of a targeted DNA microarray for the clinical evaluation of recurrent abnormalities in chronic lymphocytic leukemia.
    Patel A; Kang SH; Lennon PA; Li YF; Rao PN; Abruzzo L; Shaw C; Chinault AC; Cheung SW
    Am J Hematol; 2008 Jul; 83(7):540-6. PubMed ID: 18161787
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression and regulation of COP1 in chronic lymphocytic leukemia cells for promotion of cell proliferation and tumorigenicity.
    Fu C; Gong Y; Shi X; Shi H; Wan Y; Wu Q; Xu K
    Oncol Rep; 2016 Mar; 35(3):1493-500. PubMed ID: 26717976
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The mutational landscape of small lymphocytic lymphoma compared to non-early stage chronic lymphocytic leukemia.
    Martínez-Trillos A; Pinyol M; Delgado J; Aymerich M; Rozman M; Baumann T; González-Díaz M; Hernández JM; Alcoceba M; Muntañola A; Terol MJ; Navarro B; Giné E; Jares P; Beà S; Navarro A; Colomer D; Nadeu F; Colado E; Payer AR; García-Cerecedo T; Puente XS; López-Otin C; Campo E; López-Guillermo A; Villamor N
    Leuk Lymphoma; 2018 Oct; 59(10):2318-2326. PubMed ID: 29115891
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Increased genomic alteration complexity and telomere shortening in B-CLL cells resistant to radiation-induced apoptosis.
    Salin H; Ricoul M; Morat L; Sabatier L
    Cytogenet Genome Res; 2008; 122(3-4):343-9. PubMed ID: 19188704
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Recurrent chromosome abnormalities define nonoverlapping unique subgroups of tumors in patients with chronic lymphocytic leukemia and known karyotypic abnormalities.
    Jimenez-Zepeda VH; Chng WJ; Schop RF; Braggio E; Leis JF; Kay N; Fonseca R
    Clin Lymphoma Myeloma Leuk; 2013 Aug; 13(4):467-76. PubMed ID: 23876845
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Overexpression of Fc mu receptor (FCMR, TOSO) gene in chronic lymphocytic leukemia patients.
    Hancer VS; Diz-Kucukkaya R; Aktan M
    Med Oncol; 2012 Jun; 29(2):1068-72. PubMed ID: 21264533
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Array-based karyotyping in chronic lymphocytic leukemia (CLL) detects new unbalanced abnormalities that escape conventional cytogenetics and CLL FISH panel.
    Urbankova H; Papajik T; Plachy R; Holzerova M; Balcarkova J; Divoka M; Prochazka V; Pikalova Z; Indrak K; Jarosova M
    Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2014; 158(1):56-64. PubMed ID: 23073527
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genomic variation by whole-genome SNP mapping arrays predicts time-to-event outcome in patients with chronic lymphocytic leukemia: a comparison of CLL and HapMap genotypes.
    Schweighofer CD; Coombes KR; Majewski T; Barron LL; Lerner S; Sargent RL; O'Brien S; Ferrajoli A; Wierda WG; Czerniak BA; Medeiros LJ; Keating MJ; Abruzzo LV
    J Mol Diagn; 2013 Mar; 15(2):196-209. PubMed ID: 23273604
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Impact of gene mutations and chromosomal aberrations on progression-free survival in chronic lymphocytic leukemia patients treated with front-line chemoimmunotherapy: Clinical practice experience.
    Spunarova M; Tom N; Pavlova S; Mraz M; Brychtova Y; Doubek M; Panovska A; Skuhrova Francova H; Brzobohata A; Pospisilova S; Mayer J; Trbusek M
    Leuk Res; 2019 Jun; 81():75-81. PubMed ID: 31054420
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Molecular pathogenesis of CLL and its evolution.
    Rodríguez D; Bretones G; Arango JR; Valdespino V; Campo E; Quesada V; López-Otín C
    Int J Hematol; 2015 Mar; 101(3):219-28. PubMed ID: 25630433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The presence of high-risk chromosome aberrations in chronic lymphocytic leukaemia does not correlate with centrosome aberrations.
    Ottaggio L; Zunino A; Maric I; Grozio A; Rossi E; Spriano M; Viaggi S
    Hematol Oncol; 2008 Mar; 26(1):39-42. PubMed ID: 18050363
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Aberrant levels of SUV39H1 and SUV39H2 methyltransferase are associated with genomic instability in chronic lymphocytic leukemia.
    Carvalho Alves-Silva J; do Amaral Rabello D; Oliveira Bravo M; Lucena-Araujo A; Madureira de Oliveira D; Morato de Oliveira F; Magalhaes Rego E; Pittella-Silva F; Saldanha-Araujo F
    Environ Mol Mutagen; 2017 Dec; 58(9):654-661. PubMed ID: 28833505
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Genetic variation and risk of chronic lymphocytic leukaemia.
    Crowther-Swanepoel D; Houlston RS
    Semin Cancer Biol; 2010 Dec; 20(6):363-9. PubMed ID: 20833250
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Exploiting biological diversity and genomic aberrations in chronic lymphocytic leukemia.
    Seiffert M; Dietrich S; Jethwa A; Glimm H; Lichter P; Zenz T
    Leuk Lymphoma; 2012 Jun; 53(6):1023-31. PubMed ID: 22023519
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.